An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over RMB 29 billion (USD $4.5 billion). Typical equity allocations range from US$2-6 million in an early-stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, the US, and the EU.
The firm currently focuses on pharmaceuticals, medical devices, and IVD tools in late clinical development or early preclinical stage with high entry battier and market potential.
The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of the joint venture and strategic partnerships in the country.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply